213 related articles for article (PubMed ID: 26377590)
21. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
Cleary JM; Lima CM; Hurwitz HI; Montero AJ; Franklin C; Yang J; Graham A; Busman T; Mabry M; Holen K; Shapiro GI; Uronis H
Invest New Drugs; 2014 Oct; 32(5):937-45. PubMed ID: 24916770
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
Paz-Ares L; Forster M; Boni V; Szyldergemajn S; Corral J; Turnbull S; Cubillo A; Teruel CF; Calderero IL; Siguero M; Bohan P; Calvo E
Invest New Drugs; 2017 Apr; 35(2):198-206. PubMed ID: 27873130
[TBL] [Abstract][Full Text] [Related]
23. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [
